The BMP2 Knockout DLD-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human DLD-1 colorectal adenocarcinoma cell line, targeting the BMP2 gene. This loss-of-function model enables investigation of bone morphogenetic protein 2 (BMP2) signaling in a colorectal cancer context without clonal selection bias, suitable for pooled functional analyses of proliferation, differentiation, and EMT.
DLD-1 cells were established from a Duke??s type C colorectal adenocarcinoma of a male donor and display adherent epithelial morphology. Commonly used in colorectal cancer research, these cells carry mutations in APC, KRAS, and TP53, providing a representative genetic background for tumorigenesis and metastasis studies. Their epithelial nature and TGF-?? superfamily responsiveness make them an ideal host for BMP2 pathway dissection.
BMP2, a TGF-?? superfamily ligand, binds heteromeric complexes of BMPR1A/BMPR1B type I and BMPR2 type II receptors, activating SMAD1/5/8 through phosphorylation. These R-SMADs partner with SMAD4 to regulate transcription of ID proteins (ID1, ID2, ID3), osteogenic factors (Runx2, ALP, osteocalcin), and EMT drivers (SNAI1, TWIST). BMP2 activity is modulated by upstream inputs such as mechanical stress, parathyroid hormone, estrogen, TGF-??, Runx2, and Wnt ligands, and is antagonized by extracellular inhibitors including Noggin, Chordin, and Gremlin. In the knockout cells, disruption of BMP2 abrogates this signaling cascade, facilitating analysis of its specific contributions.
In DLD-1 colorectal cancer cells, BMP2 influences proliferation, apoptosis, and EMT programs that are central to tumor progression and metastasis. Knocking out BMP2 eliminates SMAD1/5/8 phosphorylation and downstream gene expression, enabling precise dissection of BMP2-dependent effects on migration, invasion, and mesenchymal transition. The model also allows examination of crosstalk with hyperactive Wnt signaling due to APC mutation, and supports studies of bone metastasis and drug resistance mechanisms.
Key applications include Western blotting and immunofluorescence to monitor SMAD1/5/8 activation, RT-qPCR for ID1 and SNAI1 expression, and Transwell migration/invasion assays. The cells are suitable for RNA-seq transcriptomic profiling, SMAD-responsive luciferase reporter assays, and drug target validation for BMP pathway modulators. They also serve in bone metastasis research and combinatorial treatment studies. For technical support, please contact Ascent Research.
